-$0.06 Earnings Per Share Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter

Equities research analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report ($0.06) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.05). AVEO Pharmaceuticals posted earnings per share of ($0.15) during the same quarter last year, which would suggest a positive year over year growth rate of 60%. The company is expected to issue its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full-year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.21) to ($0.11). For the next year, analysts forecast that the company will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.18) to ($0.10). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $1.61 million during the quarter, compared to analyst estimates of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.

AVEO has been the topic of several analyst reports. Zacks Investment Research lowered HEXO from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. National Securities reissued a “sell” rating and issued a $5.00 target price on shares of Oxford Square Capital in a report on Thursday, March 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $1.96.

A number of hedge funds have recently modified their holdings of AVEO. HCR Wealth Advisors purchased a new position in shares of AVEO Pharmaceuticals during the 1st quarter worth $28,000. WealthTrust Axiom LLC grew its position in shares of AVEO Pharmaceuticals by 390.5% during the first quarter. WealthTrust Axiom LLC now owns 138,505 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 110,270 shares in the last quarter. SG Americas Securities LLC purchased a new stake in AVEO Pharmaceuticals during the first quarter worth approximately $50,000. Excalibur Management Corp lifted its stake in AVEO Pharmaceuticals by 363.6% during the first quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in AVEO Pharmaceuticals by 105.5% during the first quarter. Virtu Financial LLC now owns 139,585 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 71,667 shares during the last quarter. Hedge funds and other institutional investors own 28.33% of the company’s stock.

Shares of AVEO Pharmaceuticals stock traded down $0.01 during trading on Friday, reaching $0.71. The company’s stock had a trading volume of 1,925,446 shares, compared to its average volume of 5,085,601. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59. The company has a market cap of $115.89 million, a price-to-earnings ratio of -3.74 and a beta of 0.88. The stock has a fifty day moving average price of $0.72.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Recommended Story: What is the accumulation/distribution indicator?

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.